ChromaDex Corporation (CDXC): Price and Financial Metrics
CDXC Price/Volume Stats
Current price | $1.45 | 52-week high | $2.24 |
Prev. close | $1.43 | 52-week low | $1.16 |
Day low | $1.40 | Volume | 125,600 |
Day high | $1.46 | Avg. volume | 126,761 |
50-day MA | $1.55 | Dividend yield | N/A |
200-day MA | $1.61 | Market Cap | 108.80M |
CDXC Stock Price Chart Interactive Chart >
CDXC POWR Grades
- Growth is the dimension where CDXC ranks best; there it ranks ahead of 94.65% of US stocks.
- The strongest trend for CDXC is in Quality, which has been heading up over the past 177 days.
- CDXC's current lowest rank is in the Momentum metric (where it is better than 12.19% of US stocks).
CDXC Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for CDXC is 2.98 -- better than 81.87% of US stocks.
- Price to trailing twelve month operating cash flow for CDXC is currently 51.29, higher than 93.33% of US stocks with positive operating cash flow.
- For CDXC, its debt to operating expenses ratio is greater than that reported by just 12.17% of US equities we're observing.
- Stocks that are quantitatively similar to CDXC, based on their financial statements, market capitalization, and price volatility, are IRMD, PMD, SPWR, LPRO, and STIM.
- Visit CDXC's SEC page to see the company's official filings. To visit the company's web site, go to www.chromadex.com.
CDXC Valuation Summary
- In comparison to the median Healthcare stock, CDXC's price/earnings ratio is 159.18% lower, now standing at -15.8.
- CDXC's price/sales ratio has moved down 0.2 over the prior 175 months.
Below are key valuation metrics over time for CDXC.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
CDXC | 2023-09-22 | 1.3 | 3.8 | -15.8 | -12.0 |
CDXC | 2023-09-21 | 1.3 | 3.8 | -16.1 | -12.2 |
CDXC | 2023-09-20 | 1.3 | 3.8 | -15.9 | -12.1 |
CDXC | 2023-09-19 | 1.3 | 3.9 | -16.4 | -12.5 |
CDXC | 2023-09-18 | 1.3 | 3.9 | -16.2 | -12.3 |
CDXC | 2023-09-15 | 1.4 | 4.1 | -17.0 | -13.1 |
CDXC Growth Metrics
- The year over year net income to common stockholders growth rate now stands at -28.42%.
- Its 2 year revenue growth rate is now at 38.42%.
- Its year over year cash and equivalents growth rate is now at -53.03%.

The table below shows CDXC's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 68.813 | -19.714 | -20.447 |
2022-06-30 | 69.058 | -21.893 | -28.318 |
2022-03-31 | 70.025 | -25.956 | -27.487 |
2021-12-31 | 67.449 | -24.163 | -27.128 |
2021-09-30 | 65.135 | -19.197 | -27.9 |
2021-06-30 | 62.007 | -17.123 | -23.259 |
CDXC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CDXC has a Quality Grade of C, ranking ahead of 67.33% of graded US stocks.
- CDXC's asset turnover comes in at 1.115 -- ranking 18th of 682 Pharmaceutical Products stocks.
- MYGN, REPH, and ENDP are the stocks whose asset turnover ratios are most correlated with CDXC.
The table below shows CDXC's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 1.115 | 0.615 | -3.082 |
2021-06-30 | 1.178 | 0.612 | -2.751 |
2021-03-31 | 1.276 | 0.607 | -3.100 |
2020-12-31 | 1.545 | 0.595 | -2.616 |
2020-09-30 | 1.466 | 0.586 | -2.883 |
2020-06-30 | 1.361 | 0.577 | -2.841 |
CDXC Price Target
For more insight on analysts targets of CDXC, see our CDXC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $14.80 | Average Broker Recommendation | 1.3 (Strong Buy) |
ChromaDex Corporation (CDXC) Company Bio
ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company supplies bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. The company is based inIrvine, California.
Latest CDXC News From Around the Web
Below are the latest news stories about CHROMADEX CORP that investors may wish to consider to help them evaluate CDXC as an investment opportunity.
Insider Stock Buying Reaches US$1.3m On ChromaDexMultiple insiders secured a larger position in ChromaDex Corporation ( NASDAQ:CDXC ) shares over the last 12 months... |
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMNLOS ANGELES, August 24, 2023--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, shares findings from a preclinical study, as reported in the peer-reviewed journal International Journal of Molecular Sciences by a team of scientists led by Dr. Yue Yang, Assistant Professor of Research in Pharmacology at Weill Cornell Medicine in New York. |
Analysts Expect Breakeven For ChromaDex Corporation (NASDAQ:CDXC) Before LongWith the business potentially at an important milestone, we thought we'd take a closer look at ChromaDex Corporation's... |
Q2 2023 Chromadex Corp Earnings CallQ2 2023 Chromadex Corp Earnings Call |
ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue EstimatesChromaDex (CDXC) delivered earnings and revenue surprises of 25% and 4.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
CDXC Price Returns
1-mo | -5.84% |
3-mo | -7.64% |
6-mo | -5.23% |
1-year | 19.83% |
3-year | -64.02% |
5-year | -66.20% |
YTD | -13.69% |
2022 | -55.08% |
2021 | -22.08% |
2020 | 11.37% |
2019 | 25.66% |
2018 | -41.67% |
Continue Researching CDXC
Want to do more research on ChromaDex Corp's stock and its price? Try the links below:ChromaDex Corp (CDXC) Stock Price | Nasdaq
ChromaDex Corp (CDXC) Stock Quote, History and News - Yahoo Finance
ChromaDex Corp (CDXC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...